Gilead Sciences Inc. Corporation
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild-to-moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February. Gilead in late March halted individual compassionate use requests for remdesivir as outbreaks worsened in the U.S., having provided the investigational therapy to 1,000 patients. “The system cannot support and process the overwhelming number of applications we have seen with COVID-19,” Gilead CEO Daniel O’Day said March 28. The company said in April it aims to have 500,000 treatment courses manufactured by October and 1 million by the end of 2020.
The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild-to-moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February. Gilead in late March halted individual compassionate use requests for remdesivir as outbreaks worsened in the U.S., having provided the investigational therapy to 1,000 patients. “The system cannot support and process the overwhelming number of applications we have seen with COVID-19,” Gilead CEO Daniel O’Day said March 28. The company said in April it aims to have 500,000 treatment courses manufactured by October and 1 million by the end of 2020.
Technology:
Treatments
Industry:
Pharma
Headquarters:
United States
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership